We discuss the year-1 performance of Altera, CSI's largest acquisition to day, and share our learnings from 6+ hours of interviews with Former Altera / Allscripts executives and CSI M&A execs who worked on the deal. We explore:
Why Altera's customer churn could be higher than expectedChallenges meeting meaningful use regulations and new product development on Altera's R&D budgetImpact on CSI's potential levered and unlevered IRRComparison with Acceo, CSI's first LBO in 2018